RecruitingNot Applicable

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

United States50 participantsStarted 2025-08-05

Plain-language summary

The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with exposure to at least 1 dose of Epidiolex/Epidyolex during the 13 days prior to their LMP or at any time during pregnancy.
✓. Verbal or written informed consent to participate

What they're measuring

Rate of MCM

Timeframe: Up to 12 months post birth

Trial details

NCT IDNCT06113237

SponsorJazz Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2033-08-31

Contact for this trial

Clinical Trial Disclosure & Transparency

215-832-3750 ClinicalTrialDisclosure@JazzPharma.com

View on ClinicalTrials.gov More Maternal Complications trials